Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of Eptacog Alfa (Activated) (Genetical Recombination) on Adverse Events and Serious Adverse Events in Patients With Acute Intracerebral Haemorrhage.

NCT00266006 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00266006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00266006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of Eptacog Alfa (Activated) (Genetical Recombination) on Adverse Events and Serious Adverse Events in Patients With Acute Intracerebral Haemorrhage.
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2006
Completion date
April 30, 2007
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acquired bleeding disorder, intracerebral haemorrhage